시장보고서
상품코드
1198881

동반진단 시장 : 용도별, 기술별, 자금 조달별 - 경영진 및 컨설턴트 가이드 첨부(2023-2027년)

Companion Diagnostic Markets, The Future of Diagnostics By Application, Technology and Funding. With Executive and Consultant Guides 2023-2027

발행일: | 리서치사: Howe Sound Research | 페이지 정보: 영문 541 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 동반진단 시장에 대해 조사했으며, 시장 개요와 함께 용도별, 기술별, 자금 조달별 동향 및 시장에 참여하는 기업 개요 등을 제공하고 있습니다.

목차

제1장 시장 가이드

제2장 서론과 시장 정의

제3장 시장 개요

  • 시장 진출 조직
    • 학술연구기관
    • 진단 시험 개발자
    • 계측 공급업체
    • 약품·시약 제조업체
    • 병리 공급업체
    • 독립계 임상 검사실
    • 공공 국립/지역 연구소
    • 병원 검사실
    • 임상 검사실
    • 감사 기관
    • 인증 기관
  • 맞춤형 의료와 동반진단
  • 염색체, 유전자, 에피제네틱스
  • 암 유전자
  • 산업 구조

제4장 시장 동향

  • 성장 촉진요인
  • 성장 억제요인
  • 계측, 자동화, 진단 동향

제5장 동반진단의 최근 발전

제6장 주요 기업 개요

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agilent/Dako
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics .
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Burning Rock
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellCarta
  • CellMax Life
  • Cepheid(Danaher)
  • Charles River Laboratories
  • Circulogene
  • Cizzle Biotech
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Dxcover
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Fabric Genomics
  • Fluxion Biosciences
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • Precision Medicine Group
  • PrecisionMed
  • Predicine
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sema4 Holdings
  • Sense Biodetection
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Todos Medical
  • Ultima Genomics
  • Veracyte
  • Volition
  • Vortex Biosciences
  • Vyant Bio

제7장 세계의 동반진단 시장

  • 국가별 세계 시장 - 개요
  • 용도별 세계 시장 - 개요
  • 자금 조달별 세계 시장 - 개요
  • 기술별 세계 시장 - 개요

제8장 세계의 동반진단 시장 - 용도별

제9장 세계의 동반진단 시장 - 자금 조달별

제10장 세계의 동반진단 시장 - 기술별

제11장 부록

KSM 23.02.03

OVERVIEW:

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Companion Diagnostics?
  • 2.2. The Personalized Medicine Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size.
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Personalized Medicine and Companion Diagnostics
    • 3.2.1. Basics
    • 3.2.2. Method
    • 3.2.3. Disease risk assessment
    • 3.2.4. Applications
    • 3.2.5. Diagnosis and intervention
      • 3.2.5.1. Companion Diagnostics
    • 3.2.6. Drug development and usage
    • 3.2.7. Respiratory proteomics
    • 3.2.8. Cancer genomics
    • 3.2.9. Population screening
    • 3.2.10. Challenges
    • 3.2.11. Regulatory oversight
    • 3.2.12. Intellectual property rights
    • 3.2.13. Reimbursement policies
    • 3.2.14. Patient privacy and confidentiality
  • 3.3. Chromosomes, Genes and Epigenetics
    • 3.3.1. Chromosomes
    • 3.3.2. Genes
    • 3.3.3. Epigenetics
  • 3.4. Cancer Genes
    • 3.4.1. Germline vs Somatic
    • 3.4.2. Changing Clinical Role
  • 3.5. Structure of Industry Plays a Part
    • 3.5.1. New Pharmaceutical Funding Market
    • 3.5.2. Economies of Scale
      • 3.5.2.1. Hospital vs. Central Lab
    • 3.5.3. Physician Office Labs
    • 3.5.4. Physicians and POCT

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Level of Care.
    • 4.1.2. Immuno-oncology.
    • 4.1.3. Liability.
    • 4.1.4. The Aging World
  • 4.2. Factors Limiting Growth
    • 4.2.1. State of knowledge.
    • 4.2.2. Genetic Blizzard.
    • 4.2.3. Protocol Resistance.
    • 4.2.4. Regulation and coverage.
  • 4.3. Instrumentation, Automation and Diagnostic Trends
    • 4.3.1. Traditional Automation and Centralization
    • 4.3.2. The New Automation, Decentralization and Point Of Care
    • 4.3.3. Instruments Key to Market Share
    • 4.3.4. Bioinformatics Plays a Role
    • 4.3.5. PCR Takes Command
    • 4.3.6. Next Generation Sequencing Fuels a Revolution
    • 4.3.7. NGS Impact on Pricing
    • 4.3.8. Whole Genome Sequencing, A Brave New World
    • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
    • 4.3.10. Shifting Role of Diagnostics

5. Companion Diagnostics Recent Developments

  • 5.1. Recent Developments-Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. JaxBio to Create Array-Based Cancer Tests
  • 5.3. Agilent, Qiagen Win FDA Approvals Companion Diagnostics
  • 5.4. Navignostics Using Single-Cell Spatial Proteomics
  • 5.5. HMNC Brain Health to Develop Companion Diagnostics
  • 5.6. Propath UK, Nucleai Partner on Spatial Proteomics
  • 5.7. Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based Companion Diagnostics
  • 5.8. Almac, AstraZeneca Strike CDx Development Pact
  • 5.9. Avalon GloboCare, Lu Daopei Hematology Institute to Develop Cell Therapy CDx
  • 5.10. Burning Rock Secures Lung Cancer NGS Test Approval in China
  • 5.11. TenSixteen Bio Developing Drugs, Companion NGS Tests
  • 5.12. Guardant Health Plans New Comprehensive Assay
  • 5.13. Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs
  • 5.14. Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test
  • 5.15. Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx
  • 5.16. Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug
  • 5.17. Natera Aims to Lead Market in Solid Tumor Adjuvant CDx
  • 5.18. Oncocyte Details Expansions Plans
  • 5.19. Agilent Acquires Resolution Biosciences
  • 5.20. Qiagen, Inovio Expand CDx Partnership
  • 5.21. AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
  • 5.22. NeoGenomics to Grow Through CDx Agreements, Acquisitions
  • 5.23. Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
  • 5.24. Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
  • 5.25. FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
  • 5.26. Promega to Develop MSI Assay as CDx
  • 5.27. Guardant Health to Develop CDx for Janssen
  • 5.28. Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
  • 5.29. FDA Approval for FoundationOne®CDx
  • 5.30. FDA finalizes CDx Guidance
  • 5.31. QIAGEN Launches CDx Therascreen BRAF Test

6. Profiles of Key Players

  • 6.1. 10x Genomics, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. AccuraGen Inc.
  • 6.4. Adaptive Biotechnologies
  • 6.5. Aethlon Medical
  • 6.6. Agilent/Dako
  • 6.7. Anchor Dx
  • 6.8. ANGLE plc
  • 6.9. ARUP Laboratories
  • 6.10. AVIVA Systems Biology
  • 6.11. Baylor Miraca Genetics Laboratories
  • 6.12. Beckman Coulter Diagnostics
  • 6.13. Becton, Dickinson and Company
  • 6.14. BGI Genomics Co. Ltd
  • 6.15. Bioarray Genetics
  • 6.16. Biocartis
  • 6.17. Biocept, Inc.
  • 6.18. Biodesix Inc.
  • 6.19. BioFluidica
  • 6.20. BioGenex
  • 6.21. BioIVT
  • 6.22. Biolidics .
  • 6.23. bioMérieux Diagnostics
  • 6.24. Bioneer Corporation
  • 6.25. Bio-Rad Laboratories, Inc
  • 6.26. Bio-Reference Laboratories
  • 6.27. Bio-Techne
  • 6.28. Bioview
  • 6.29. Bolidics
  • 6.30. Boreal Genomics
  • 6.31. Bristol-Myers Squibb
  • 6.32. Burning Rock
  • 6.33. Cardiff Oncology
  • 6.34. Caris Molecular Diagnostics
  • 6.35. Castle Biosciences, Inc.
  • 6.36. CellCarta
  • 6.37. CellMax Life
  • 6.38. Cepheid (Danaher)
  • 6.39. Charles River Laboratories
  • 6.40. Circulogene
  • 6.41. Cizzle Biotech
  • 6.42. Clinical Genomics
  • 6.43. Cytolumina Technologies Corp.
  • 6.44. Datar Cancer Genetics Limited
  • 6.45. Diagnologix LLC
  • 6.46. Diasorin S.p.A.
  • 6.47. Dxcover
  • 6.48. Element Biosciences
  • 6.49. Enzo Biochem
  • 6.50. Epic Sciences
  • 6.51. Epigenomics AG
  • 6.52. Eurofins Scientific
  • 6.53. Fabric Genomics
  • 6.54. Fluxion Biosciences
  • 6.55. Freenome
  • 6.56. FUJIFILM Wako Diagnostics
  • 6.57. Fyr Diagnostics
  • 6.58. GeneFirst Ltd.
  • 6.59. Genetron Holdings
  • 6.60. GenomOncology
  • 6.61. GILUPI Nanomedizin
  • 6.62. Guardant Health
  • 6.63. HansaBiomed
  • 6.64. HeiScreen
  • 6.65. Helomics
  • 6.66. HTG Molecular Diagnostics
  • 6.67. iCellate
  • 6.68. Illumina
  • 6.69. Incell Dx
  • 6.70. Inivata
  • 6.71. INOVIQ
  • 6.72. Integrated Diagnostics
  • 6.73. Invitae Corporation
  • 6.74. Invivogen
  • 6.75. Invivoscribe
  • 6.76. Janssen Diagnostics
  • 6.77. Lunglife AI Inc
  • 6.78. MDNA Life SCIENCES, Inc.
  • 6.79. MDx Health
  • 6.80. Menarini Silicon Biosystems
  • 6.81. Mesa Laboratories, Inc.
  • 6.82. Millipore Sigma
  • 6.83. Miltenyi Biotec
  • 6.84. miR Scientific
  • 6.85. Myriad Genetics/Myriad RBM
  • 6.86. NantHealth, Inc.
  • 6.87. Natera
  • 6.88. NeoGenomics
  • 6.89. NGeneBio
  • 6.90. Novogene Bioinformatics Technology Co., Ltd.
  • 6.91. Oncocyte
  • 6.92. OncoDNA
  • 6.93. Ortho Clinical Diagnostics
  • 6.94. Oxford Nanopore Technologies
  • 6.95. PamGene
  • 6.96. Panagene
  • 6.97. Perkin Elmer
  • 6.98. Personal Genome Diagnostics
  • 6.99. Personalis
  • 6.100. Precipio
  • 6.101. Precision Medicine Group
  • 6.102. PrecisionMed
  • 6.103. Predicine
  • 6.104. Promega
  • 6.105. Qiagen
  • 6.106. Rarecells SAS
  • 6.107. RareCyte
  • 6.108. Roche Molecular Diagnostics
  • 6.109. Screencell
  • 6.110. Sema4 Holdings
  • 6.111. Sense Biodetection
  • 6.112. Siemens Healthineers
  • 6.113. simfo GmbH
  • 6.114. Singlera Genomics Inc.
  • 6.115. Singular Genomics
  • 6.116. Singulomics
  • 6.117. SkylineDx
  • 6.118. Standard BioTools
  • 6.119. Stilla Technologies
  • 6.120. Sysmex Inostics
  • 6.121. Tempus Labs, Inc.
  • 6.122. Thermo Fisher Scientific Inc.
  • 6.123. Todos Medical
  • 6.124. Ultima Genomics
  • 6.125. Veracyte
  • 6.126. Volition
  • 6.127. Vortex Biosciences
  • 6.128. Vyant Bio

7. The Global Market for Companion Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table-Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Application - Overview
    • 7.2.1. Table-Global Market by Application
    • 7.2.2. Chart-Global Market by Application-Base/Final Year Comparison
    • 7.2.3. Chart-Global Market by Application-Base Year
    • 7.2.4. Chart-Global Market by Application-Final Year
    • 7.2.5. Chart-Global Market by Application-Share by Year
  • 7.3. Global Market Funding Source - Overview
    • 7.3.1. Table-Global Market by Funding Source
    • 7.3.2. Chart-Global Market Funding Source-Base/Final Year Comparison
    • 7.3.3. Chart-Global Market Funding Source-Base Year
    • 7.3.4. Chart-Global Market Funding Source-Final Year
    • 7.3.5. Chart-Global Market Funding Source-Share by Year
  • 7.4. Global Market Technology - Overview
    • 7.4.1. Table-Global Market by Technology
    • 7.4.2. Chart-Global Market Technology-Base/Final Year Comparison
    • 7.4.3. Chart-Global Market Technology-Base Year
    • 7.4.4. Chart-Global Market Technology-Final Year
    • 7.4.5. Chart-Global Market Technology-Share by Year

8. Global Companion Diagnostic Markets-By Application

  • 8.1. Oncology
    • 8.1.1. Table Oncology-by Country
    • 8.1.2. Chart - Oncology Growth
  • 8.2. Neurology
    • 8.2.1. Table Neurology-by Country
    • 8.2.2. Chart - Neurology Growth
  • 8.3. Cardiology
    • 8.3.1. Table Cardiology-by Country
    • 8.3.2. Chart - Cardiology Growth
  • 8.4. Other Application
    • 8.4.1. Table Other Application-by Country
    • 8.4.2. Chart - Other Application Growth

9. Global Companion Diagnostic Markets-Funding Source

  • 9.1. Global Market Pharmaceutical
    • 9.1.1. Table Pharmaceutical-by Country
    • 9.1.2. Chart - Pharmaceutical Growth
  • 9.2. Global Market Venture
    • 9.2.1. Table Venture-by Country
    • 9.2.2. Chart - Venture Growth
  • 9.3. Global Market Clinical
    • 9.3.1. Table Clinical-by Country
    • 9.3.2. Chart - Clinical Growth
  • 9.4. Global Market Other Funding
    • 9.4.1. Table Other Funding-by Country
    • 9.4.2. Chart - Other Funding Growth

10. Global Companion Diagnostic Markets-Technology

  • 10.1. Global Market Next Generation Sequencing
    • 10.1.1. Table Next Generation Sequencing-by Country
    • 10.1.2. Chart - Next Generation Sequencing Growth
  • 10.2. Global Market PCR
    • 10.2.1. Table PCR-by Country
    • 10.2.2. Chart - PCR Growth
  • 10.3. Global Market IHC/ISH
    • 10.3.1. Table IHC/ISH-by Country
    • 10.3.2. Chart - IHC/ISH Growth
  • 10.4. Global Market Other Technology
    • 10.4.1. Table Other Technology-by Country
    • 10.4.2. Chart - Other Technology Growth

11. Appendices

  • 11.1. United States Medicare System: Clinical Laboratory Fees Schedule
  • 11.2. The Most Used IVD Assays
  • 11.3. The Highest Grossing Assays
  • 11.4. Pharmacogenomic Biomarkers in Drug Labeling
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제